Week in Review: Lee's Pharm Pays $50 Million for Novel Cancer Drug from Sorrento
October 11, 2014 at 04:18 AM EDT
Lee's Pharm in-licensed China rights to a immune-oncological PD-L1 monoclonal antibody from Sorrento Therapeutics of San Diego in a deal worth up to $50 million; Alliance Boots received China regulatory permission to acquire a 12% stake in Nanjing Pharmaceutical for $91 million; Sihuan Pharma signed a collaborative agreement to develop a treatment for Ebola discovered by the Institute of Microbiology and Epidemiology of China's Academy of Military Medical Sciences; ContraFect of New York and China's National Institute for Viral Disease Control and Prevention formed a collaboration to advance ContraFect's universal treatment for flu; and Hony Capital, the private equity arm of Beijing-based computer maker Lenovo, invested in Shanghai Yangsi Hospital, a private hospital in Shanghai. More details.... Stock Symbols: (HK: 0950) (NSDQ: SRNE) (SHA: 600713) (HK: 460) (NSDQ: CRFX) Share this with colleagues: // //